Poster Viewing Sessions
Four poster viewing sessions are organized during the 30th Annual Meeting.
Thursday, 17 November 2022
| 12:15 - 13:30 | Poster Viewing Session I - Basic Studies part 1 Prof. Hans Lassmann, Hans-Peter Hartung, Catherine Lubetzki | |
| 17:15 - 18:15 | Poster viewing II - Clinical + Treatment Prof Per Soelberg Sørensen, Letizia Leocani, Gilles Edan |
Friday, 18 November 2022
| 10:00 - 10:30 | Poster Viewing Session III - Epidemiology + Investigations Maria Trojano, Xavier Montalban, Prof Dr Gavin Giovannoni | |
| 13:00 - 14:00 | Poster viewing IV - Basic Studies part 2 Prof Dr Jacqueline Palace, Ariel Miller, Prof Dr Kazuo Fujihara |
During those sessions, our Young Investigators will present their posters to the jury onsite. E-posters will be also available for consultation on the live-streaming platform and on the ECF website.
The winners of the 5 Young Investigators Awards (one Award per category) will be announced on Friday, 18 November 2022 from 17:20 - 17:30.
The winners will also present their posters during the Young Investigators Awards presentations which will be held on Saturday, 19 November 2022 from 10:30 - 11:00.
| Hour Location |
Title | Location |
|---|---|---|
|
12:15 - 13:30 |
Poster Viewing Session I (Basic Studies Part. 1) Hans Lassmann, Hans-Peter Hartung, Prof. Dr Catherine Lubetzki |
|
| -- |
ID 5: NAWM in MS: loss of oligodendrocytes and lesion depended microglia activation Ms Wiebke Kessler |
|
| -- |
ID 6: A human system studying myelin phagocytosing and its effect on oligodendrocytes Ms Laura Eleonora Schmitz-Gielsdorf |
|
| -- |
ID 7: Human iPSC-derived oligodendrocytes and organoids to identify promyelinating drugs Ms Farina Windener |
|
| -- |
ID 16: Model for Microglial-axon contacts at the Node of Ranvier in Multiple Sclerosis Dr João Marcos Brandet |
|
| -- |
ID 20: Clustering Multiple Sclerosis Lesions by Spatial, Geometric and Textural Domains Mr Bastien Caba |
|
| -- |
ID 22: Vessel-associated extracellular matrix proteins modulate MS pathology Dr Marco Pisa |
|
| -- |
ID 28: Multiple Sclerosis Multidisciplinary Care: A National Survey MS Liesbeth Van HIjfte |
|
| -- |
ID 35: A Deep Learning Algorithm for Multi-Modal Multiple Sclerosis Lesion Segmentation Mr Bastien Caba |
|
| -- |
ID 40: Lesion Classification in Multiple Sclerosis Using Texture-Derived Super-Voxels Mr Quentin Spinat |
|
| -- |
ID 29: Switch to oral cladribine from first line DMD in MS: Interim Analysis of CLADCROSS Dr Nicolaos Grigoriadis |
|
| -- |
ID 39: The role of B cell-derived IL-10 in regulation of chronic CNS inflammation Dr Darius Häusler |
|
|
17:15 - 18:15 |
Poster Viewing Session II (Clinical + Treatment) Per Soelberg Sørensen, Letizia Leocani, Gilles Edan |
|
| -- |
ID 19: Evobrutinib acts on microglia: therapeutic implication in progression of MS? Dr Anastasia Geladaris |
|
| -- |
ID 33: Cladribine treatment in multiple sclerosis patients in Poland during COVID-19. Dr Aleksandra Pogoda-Wesołowska |
|
| -- |
ID 38: The relation between SDMT, fatigue, depression and anxiety in a Belgian MS cohort Dr Serena Borrelli |
|
| -- |
ID 42: The efficacy of Natalizumab in Pediatric-Onset Multiple Sclerosis patients Dr Marta Gaggiola |
|
| -- |
ID 43: Alemtuzumab following natalizumab in pediatric- and adult-onset multiple sclerosis Dr Marta Gaggiola |
|
| -- |
ID 44: Quantifying MS Disability: From EDSS to Walking Bouts as possible new Biomarkers Mr Thorben Beyer |
|
| -- |
ID 54: Transcranial direct current stimulation applied in EAE mouse model Dr Silvia Marenna |
|
| -- |
ID 62: Neurophysiological predictors of response to neurorehabilitation plus rTMS in MS Mr Michelangelo Dini |
|
| -- |
ID 12: Tolebrutinib Two-Year Safety and Efficacy in Relapsing Multiple Sclerosis Patients Dr Robert Fox |
|
| -- |
ID 13: CNM-Au8 Phase 2 VISIONARY-MS Phase II Clinical Trial Results Dr Robert Glanzman |
|
| -- |
ID 14: Tolebrutinib Two-Year MRI Outcomes in Patients with Relapsing Multiple Sclerosis Prof Dr Daniel Reich |
|
| -- |
ID 15: Correlation between clinical and biomarker data in ATA188-treated progressive MS Dr Jonathan Willmer |
|
| -- |
ID 23: Physicians’ reason for DMT choice and unmet need in US patients with nonactive PPMS Dr Jonathan Willmer |
|
| -- |
ID 25: PROGRESSIVE MULTIPLE SCLEROSIS PREDICTS EPISODIC MEMORY IMPAIRMENT AFTER ONE YEAR Ms Daniela Taranu |
|
| -- |
ID 27: Evaluation of patient-reported outcomes: CLAWIR study 6-month interim analysis Dr Joachim Richter |
|
| -- |
ID 32: A consensus for the Immune reconstitution therapy in Relapsing Multiple Sclerosis Prof Patrick Vermersch |
|
| -- |
ID 34: Early MRI parameters associated with long-term outcomes in ozanimod MS studies Dr Diego Silva |
|
| -- |
ID 36: Cognitive Processing Speed at First Relapse in MS: Ozanimod vs Interferon β-1a Dr Diego Silva |
|
| -- |
ID 49: Best supportive care for PPMS prior to ocrelizumab: RETRO PPMS final results Dr Tanja Meier |
|
| -- |
ID 50: MoOzaRt: Impact of ocrelizumab on patient-reported fatigue in RMS patients Mr Walter Siegenthaler |
|
| -- |
ID 60: Real-world data from MSBase Registry in MOG Antibody Associated Disease. Dr Barbara Willekens |
|
| -- |
ID 64: Real-world ocrelizumab treatment in patients with PPMS – a CONFIDENCE interim data Prof Dr Martin Weber |
|
| -- |
ID 65: Measuring outcomes in MS studies: Tracing the pervasive implications of PIRA Prof Dr Jeremy Hobart |
| Hour Location |
Title | Location |
|---|---|---|
|
10:00 - 10:30 |
Poster Viewing Session III (Epidemiology + Investigations) Maria Trojano, Xavier Montalban, Gavin Giovannoni |
|
| -- |
ID 8: High socioeconomic impact on prescription behavior of on-label DMT in MS Dr Sara Samadwadeh |
|
| -- |
ID 17: Could the absence of risk factors delay the diagnosis of MS?.Mexican cohort Dr Daniela Alexia Leon Castillo |
|
| -- |
ID 18: Could be related the RFNL thinning as a predictive for multiple sclerosis severity? Dr Daniela Alexia Leon Castillo |
|
| -- |
ID 26: Longitudinal fixel-based white matter damage predicts cognitive decline in MS Dr Ismail Koubiyr |
|
| -- |
ID 45: Genetic study on iron metabolism genes implicates HIF1A in MS progression Dr Antonino Giordano |
|
| -- |
ID 51: Intrathecal Opsonins and Spinal Cord Axonal Loss in Multiple Sclerosis Mr Alex Waldman |
|
| -- |
ID 52: Socioeconomic status and access to DMT in multiple sclerosis Colombian patients Dr Adriana Casallas-Vanegas |
|
| -- |
ID 3: Digital biomarkers are associated with regional brain atrophy in RIS Dr Mikael Cohen |
|
| -- |
ID 4: Bedside digital videooculography as a biomarker of neurodegenerescence in MS Dr Mikael Cohen |
|
| -- |
ID 24: Alternative spliced genes in peripheral blood mononuclear cells of MS patients Mrs Isabel Brichette Mieg |
|
| -- |
ID 30: Combining mfVEP and VBM-OCT to Monitor Inflammation and Neurodegeneration in PMS Dr Su-Chun Huang |
|
| -- |
ID 31: Remibrutinib exhibits improved target selectivity and potency in vitro Dr Marina Ziehn |
|
|
13:00 - 14:00 |
Poster Viewing Session IV (Basic Studies Part 2) Prof Dr Jacqueline Palace, Ariel Miller, Prof Dr Kazuo Fujihara |
|
| -- |
ID 46: A potential protective role of Nurr1 in multiple sclerosis motor cortex Dr Jonathan Pansieri |
|
| -- |
ID 47: Transcortical Inflammation and Expanding Cortical Demyelination in Progressive MS Ms Betul Okutan |
|
| -- |
ID 48: IgG & IgM changes in PPMS vs RRMS patients during long-term CD20 depleting therapy Ms Himali Bergeron - Vitez |
|
| -- |
ID 53: DMF transcriptional signature in PBMCs of MS patients and clinical association Ms Alicia Sánchez Sanz |
|
| -- |
ID 55: Determining immunoglobulin G subclass profiles of tertiary lymphoid structures Dr Rachael Kee |
|
| -- |
ID 56: The role of 5-HT2BR in the modulation of macrophages-induced Th17-immunity in MS Dr Mikhail Melnikov |
|
| -- |
ID 57: Breakthrough SARS-CoV-2 infection after 3rd mRNA vaccination in a-CD20 MS patients Dr Frederik Novak Stenstad |
|
| -- |
ID 58: Spatial transcriptomics of compartmentalised inflammation in Multiple Sclerosis Dr Michelle Naughton |
|
| -- |
ID 61: Visual and motor function in experimental autoimmune encephalomyelitis 61 Rossi Elena |
|
| -- |
ID 21: Age-related grey matter demyelination and neurodegeneration in a mouse model of MS Dr Valeria Ramaglia |
|
| -- |
ID 59: Siponimod treatment of chronic EAE induces an altered microglial phenotype Dr Leila Husseini |
|
| -- |
ID 63: Transcorneal retinal neuromodulation: preclinical proof of concept Dr Valerio Castoldi |
|
|
17:20 - 17:30 |
Announcement of the Young Investigator Awards winners |
| Hour Location |
Title | Location |
|---|---|---|
|
10:30 - 11:00 |
Young Investigator Awards |